NCT05383196 2026-02-11Onvansertib + Paclitaxel In TNBCDana-Farber Cancer InstitutePhase 1/2 Active not recruiting50 enrolled
NCT06106308 2026-01-12Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS MutationCardiff OncologyPhase 2 Active not recruiting113 enrolled